Slide 1: Exchange cover letter: Investor Presentation Q4 FY24
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/SP/2024-25/49 June 27, 2024 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corpo
Slide 2: Investor Presentation June 2024
Investor Presentation June 2024
Slide 3: Core Values
Biocon is a technology-enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high- quality, affordable therapies that can lower costs, increase access and improve treatment outcomes. Value Creation through Innovation & Differe
Slide 4: Biocon at a Glance
Biocon at a Glance ₹15,621 Cr | 16,300+ Rank #8 Among Top 10 Global Total Employees# ~ $1.9 Bn Biotech, Pharma & Total Revenue* Biopharma Sector** 1,700+ 100+ 8 cGMP approvals from Patents# Manufacturing International regulatory agencies units# 120+ 14 of top 20 Top 25 Countries where our Pharma com
Slide 5: Building Biocon
Building Biocon
Slide 6: Biocon: One Company, with multiple value propositions across its verticals
Biocon: One Company, with multiple value propositions across its verticals From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality & affordable healthcare products & services, globally Ensuring access through quality, affordability, reliability ▪ Lead
Slide 7: Generics Business at a Glance
Generics Business at a Glance Presence in R&D team of 7 90+ 750+ 100+ State-of-the-art cGMP approvals 500+ countries including U.S., manufacturing received from international Scientists & Global Europe & large EMs sites regulatory agencies Postgraduates customer reach Portfolio comprises 120+ 500+ 3
Slide 8: Generics: API & Formulations - Growth Levers
Generics : API & Formulations - Growth Levers Strengths built over the years Product Portfolio Expansion Capacities Additions & Expansion • Expertise in fermentation technology, large scale • API - Expanding portfolio beyond fermentation and • Immunosuppressants API (Visakhapatnam) chromatography &
Slide 9: Generics: Our Key APIs and Formulations
Generics : Our Key APIs and Formulations Launched Approved F O R M U L AT I O N S APIs* Dev Markets: Therapeutic Area Molecule US MoW1 ex-US Therapeutic Area Molecule Therapeutic Area Molecule Rosuvastatin Calcium UK, EU$ Tacrolimus Simvastatin Apixaban Atorvastatin Mycophenolate Mofetil Atorvastati
Slide 10: Biosimilars Business at a Glance
Biosimilars Business at a Glance Global reach in Diverse global Top 15 85+ 120+ in global cGMP approvals talent pool of countries including U.S., biomanufacturing received from key regulatory ~5,500 Europe and Emerging Markets capacity agencies people 390+* Portfolio comprises 9 Patents 20 biosimila
Slide 11: Biosimilars: Unique, fully integrated capabilities from lab to market
Biosimilars: Unique, fully integrated capabilities from lab to market Research & Development Global Scale Manufacturing Commercialization Process & Product Development Mammalian & microbial tech platforms Commercial footprint in 100+ countries 3 Manufacturing Sites Analytical & Bioanalytical Capabil
Slide 12: Biosimilars: Leading global player with a strong track record of success
Biosimilars: Leading global player with a strong track record of success Built on a 40+ year legacy of cutting-edge science …with a strong track record in an attractive market • Invested >$1 Bn in biosimilars ahead of its peers to build • Achieved many ‘firsts’ in the industry - first to receive exp
Slide 13: Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars
Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars Oncology Immunology Ophthalmology Bone Health Diabetes Others Therapy Area • Pegfilgrastim • Adalimumab • Aflibercept • rh-Insulin Approved or • Trastuzumab • Etanercept • Glargine U100 Commercial • Bevacizumab • Aspart • Denos
Slide 14: Novel Molecules: Itolizumab
Novel Molecules: Itolizumab Pushing to deliver impactful innovations in collaboration with Equillium Inc. ✓ Pivotal Phase III Study initiated in April 2022 for use in First-Line treatment of aGVHD; Acute Graft- enrollment ongoing Itolizumab Versus-Host ✓ Received U.S. FDA Fast Track & Orphan Drug De
Slide 15: Novel Molecules: Bicara Therapeutics - BCA101
Novel Molecules: Bicara Therapeutics* - Dual Action | Dual Impact The precision of targeted therapies | The power of tumor modulators ✓ Lead product candidate, BCA101 (EGFR / TGF-β-trap) demonstrates tumor target engagement and clinical activity ✓ BCA101 + pembrolizumab combination dose expansion st
Slide 16: Syngene's broad capabilities, spanning the value chain
Syngene’s broad capabilities, spanning the value chain, facilitate integration to captures additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability a
Slide 17: Syngene: Strategic Priorities
Syngene: Strategic Priorities Research: Research: Discovery Services Dedicated Centers Operational Excellence Emphasize operational excellence Provide end-to-end therapeutic Further enhance our current through improved productivity and discovery and preclinical collaborations with Amgen, Bristol eff
Slide 18: Q4 and FY24 Highlights
Q4 and FY24 Highlights
Slide 19: Financial Highlights – Q4 FY24
Financial Highlights – Q4 FY24 In INR Cr Q4 FY24 Q4 FY23 Q3 FY24 YoY (%) QoQ(%) Generics 719 744 703 (3) 2 Biosimilars 2,358 2,102 2,4831 12 (5) Novels - 19 - - - Research Services 917 994 854 (8) 7 Revenue from Operations 3,917 3,774 3,9541 4 (1) Total Revenue 3,966 3,929 4,5192 1 (12) R&D 246 342
Slide 20: Financial Highlights – FY24
Financial Highlights – FY24 In INR Cr FY24 FY23 YoY (%) Generics 2,799 2,765 1 1 Biosimilars 8,824 5,584 58 Novels - 19 - Research Services 3,489 3,193 9 Revenue from Operations 14,7561 11,174 32 Total Revenue 15,6212 11,550 35 R&D 1,154 1,119 3 % of Revenue (Ex. Syngene) 10% 14% Core EBITDA3 4,195
Slide 21: Biocon Generics: Q4 & full year FY24 Business Update
Biocon Generics: Q4 & full year FY24 Business Update Strong traction in the formulations business (up 36% YoY), led by growth of Q4 Q4 Q3 In ₹ Cr YoY % QoQ % statins and immunosuppressants across all major geographies during FY24 FY24 FY23 FY24 Revenue from 719 744 703 (3) 2 Operations Despite the c
Slide 22: Biocon Biologics: Biosimilars – Q4 FY24 Business Update
Biocon Biologics: Biosimilars – Q4 FY24 Business Update Key Products’ Market Share1 United States 1st quarter where Biocon Biologics directly managed the acquired business across geographies Mar-24 Jan-24 Mar-23 Fulphila (bPegfilgrastim) 21% 19% 14% Ogivri (bTrastuzumab) 18% 14% 10% Continued increa
Slide 23: Biocon Biologics: Biosimilars – Q4 & full year FY24 Financial Update
Biocon Biologics: Biosimilars – Q4 & full year FY24 Financial Update Q4 Q4 Q3 YoY QoQ In INR CR FY24 FY23 FY24 % % Revenue from 2,358 2,102 2,4832 12 103 Q4 revenue grew 12% vs. last year and 10% on a sequential quarter Operations basis after adjusting for income from the non-core BFI divesture in Q
Slide 24: Biocon Biologics: Biosimilars – Q4 FY24 Other Business Updates
Biocon Biologics: Biosimilars – Q4 FY24 Other Business Updates FDA accepted bUstekinumab filing and settled with J&J for a launch in the U.S. no later than February 2025 – will be among the first wave of entrants Settled with Bayer and Regeneron for a launch of bAflibercept in Canada no later than J
Slide 25: Novels: Q4 & FY24 Update
Novels : Q4 & FY24 Update Itolizumab (partnered with Equillium) Equillium presented positive data from Phase 1b EQUALISE Study of itolizumab in patients with lupus nephritis at the annual meetings of America Society of Nephrology and the American College of Rheumatology In April 2024, Equillium anno
Slide 26: Syngene: Q4 and full year FY24 Update
Syngene: Q4 and full year FY24 Update Q4 Q4 Q3 YoY QoQ Q4 and FY24 impacted by lower demand for research services stemming In INR Cr FY24 FY23 FY24 % % from a slowdown in US biotech funding environment Revenue from 917 994 854 (8) 7 Operations Full year performance supported by strong growth in deve
Slide 27: Environment, Social, Governance
Environment, Social, Governance
Slide 28: ESG: A Culture of Purpose, Ethics & Equity
ESG: A Culture of Purpose, Ethics & Equity Disclosures and Going beyond financials to have a positive impact Recognitions Published 1st GRI aligned Our ESG Strategy Pillars Integrated Report & 2nd BRSR Report for FY23 Improved ESG score of Improve access to high quality therapeutics to drive ‘Patien
Slide 29: Progressed to Integrated Reporting
Progressed to Integrated Reporting Continuously improving disclosures towards better transparency 1st GRI aligned Integrated Report for FY23 with many maiden disclosures Outcome of Gender Pay Gap Analysis Alignment with TCFD Outcome of Water Risk Assessment Outcome of Biodiversity Impact Assessment
Slide 30: Annexures
Annexures
Slide 31: Our Evolution Over the Years
Our Evolution Over the Years 1978 2000 2005 2010 2019 2023 to to to to to & 1999 2004 2009 2018 2022 beyond An Enzymes Company Transforming into a Building the Base Building Scale for Global Poised for Global Working on Becoming a Biopharma Company Business and Expertise in impact Impact: Biosimilar
Slide 32: With many firsts, Biocon is ahead of the curve
With many firsts, Biocon is ahead of the curve 2000 2006 2016 2019 2023 1993 to to to to & 2004 2015 2018 2022 beyond ISO 9001 Certification for a Established Clinigene – Launched Nimotuzumab, Biosimilar approved in bGlargine commercialized in Received approval of Life Science Company Clinical Resea
Slide 33: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 34: Thank You
Thank You $ Biocon 4 on iS hares @> ye. Rote re Oc ee ee oe tet oe, ete e ra sly . we ee wt “ete eS. Cy “ : Aw** Relentless Pursuit. Differentiated Growth. O~»